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a  b  s  t  r  a  c  t
Background:  A  prophylactic  human  papillomavirus  (HPV)  vaccine  targeting  oncogenic  HPV types  in addi-
tion  to  HPV-16  and  -18  may  broaden  protection  against  cervical  cancer.  Two  Phase  I/II,  randomized,
controlled  studies  were  conducted  to  compare  the  immunogenicity  and  safety  of  investigational  tetrava-
lent HPV  L1  virus-like  particle  (VLP)  vaccines,  containing  VLPs  from  two  additional  oncogenic  genotypes,
with  the  licensed  HPV-16/18  AS04-adjuvanted  vaccine  (control)  in  healthy  18–25 year-old  women.
Methods:  In one  trial (NCT00231413),  subjects  received  control  or one  of  6 tetravalent  HPV-16/18/31/45eywords:
uman papillomavirus vaccine
etravalent vaccine
ivalent vaccine
mmunogenicity
AS04  vaccine  formulations  at months  (M)  0,1,6. In a second  trial (NCT00478621),  subjects  received  control
or  one  of  5  tetravalent  HPV-16/18/33/58  vaccines  formulated  with  different  adjuvant  systems  (AS04,  AS01
or AS02),  administered  on  different  schedules  (M0,1,6  or  M0,3  or M0,6).
Results:  One  month  after  the third  injection  (Month  7),  there  was  a consistent  trend  for  lower  anti-HPV-afety 16  and -18  geometric  mean  antibody  titers (GMTs)  for tetravalent  AS04-adjuvanted  vaccines  compared
mmune interference with  control.  GMTs  were  statistically  signiﬁcantly  lower  for an  HPV-16/18/31/45  AS04  vaccine  containing
Abbreviations: AE, adverse event; ANOVA, analysis of variance; ATP, according-to-protocol; CD40L, CD40 ligand; CI, conﬁdence interval; CIN, cervical intraepithelial
eoplasia; Ctrl, control; ELISA, enzyme-linked immunosorbent assay; EU, ELISA units; GMT, geometric mean antibody titer; HPV, human papillomavirus; IFN, interferon; IL,
nterleukin; LU, Luminex units; M,  months; MLIA, multiplex Luminex immunoassay; MPL, 3-O-desacyl-4′-monophosphoryl lipid A; No., number; PBNA, pseudovirion-based
eutralization assay; PCR, polymerase chain reaction; QS21, Quillaja saponaria Molina fraction 21; SAE, serious adverse event; TNF, tumor necrosis factor; VLP, virus-like
article.
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20/20/10/10  g VLPs  for both  anti-HPV-16  and  anti-HPV-18  antibodies,  and  for  an  HPV-16/18/33/58  AS04
vaccine  containing  20/20/20/20  g  VLPs  for  anti-HPV-16  antibodies.  There  was  also  a trend  for  lower
HPV-16  and  -18-speciﬁc  memory  B-cell responses  for tetravalent  AS04  vaccines  versus  control.  No such
trends  were  observed  for  CD4+ T-cell  responses.  Immune  interference  could  not  always  be  overcome  by
increasing  the  dose  of  HPV-16/18  L1 VLPs  or by using  a different  adjuvant  system.  All  formulations  had
acceptable  reactogenicity  and  safety  proﬁles.  Reactogenicity  in the  7-day  post-vaccination  period  tended
to  increase  with  the introduction  of additional  VLPs,  especially  for formulations  containing  AS01.
Conclusions:  HPV-16  and -18  antibody  responses  were  lower  when  additional  HPV  L1 VLPs  were  added
to the  HPV-16/18  AS04-adjuvanted  vaccine.  Immune  interference  is  a complex  phenomenon  that  cannot
always be overcome  by changing  the antigen  dose  or adjuvant  system.
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G. Introduction
More than 500,000 new cases of invasive cervical cancer
re diagnosed each year worldwide, resulting in approximately
75,000 deaths [1]. Persistent infection with an oncogenic human
apillomavirus (HPV) type is a prerequisite for the development
f cervical cancer [2]. Approximately 70% of cervical cancer cases
orldwide are associated with HPV-16 and/or HPV-18 [3,4]. Other
ommon oncogenic HPV types associated with cervical cancer
nclude HPV-31, -33, -35, -45, -52 and -58 [4,5,6].
Two prophylactic HPV vaccines against cervical cancer are
urrently licensed: the HPV-16/18 AS04-adjuvanted vaccine
Cervarix®) and the HPV-6/11/16/18 vaccine (Gardasil®)3, both
onsisting of virus-like particles (VLPs) composed of L1 major cap-
id proteins. In clinical trials, these vaccines had high protective
fﬁcacy against persistent infection and cervical intraepithelial
eoplasia (CIN) associated with HPV-16/18 and some oncogenic
on-vaccine HPV types [7–10]. Moreover, regardless of HPV type
n the lesion, the HPV-16/18 AS04-adjuvanted vaccine reduced the
ncidence of CIN3+ by 93% in women who were HPV-naive at base-
ine [11].
Prophylactic vaccines which include additional oncogenic HPV
1 VLPs should theoretically broaden the protection against cervical
nd possibly other cancers. However, the challenge of developing
uch vaccines is to ensure that immunogenicity and efﬁcacy against
PV-16/18 (the two most prevalent types in cervical cancer) are
ot compromised by the introduction of additional HPV L1 VLPs,
nd that the safety proﬁle and number of doses required are still
cceptable. Herein we report the results of two studies evaluating
he immunogenicity and safety of two investigational tetravalent
PV L1 VLP vaccines (HPV-16/18/31/45 and HPV-16/18/33/58 vac-
ines). In these two studies, varying dosages of HPV L1 VLPs (10,
0 or 30 g), adjuvant systems (AS04, AS01 or AS02 [12,13]) and
osing regimens (0,1,6 months or 0,3 months or 0,6 months) were
valuated.
. Materials and methods
.1. Study design
We  report data from two separate clinical trials of inves-
igational tetravalent HPV vaccines. In both trials, the licensed
PV-16/18 AS04-adjuvanted vaccine (Cervarix®), containing 20 g
f each L1 VLP, was used as a control. The amounts of HPV L1
LPs, formulations and dosing intervals used for the investigational
etravalent vaccines are summarized in Table 1.
3 Cervarix is a registered trade mark of the GlaxoSmithKline group of companies.
ardasil is a registered trade mark of Merck & Co., Inc.© 2014  Elsevier  Ltd.  All rights  reserved.
Study TETRA-051 (NCT00231413) was  a Phase I/II, double-blind,
randomized, controlled, dose-ranging trial evaluating an AS04-
adjuvanted HPV-16/18/31/45 vaccine, conducted at 11 centers in
Belgium and the USA between March 2005 and August 2009. Sub-
jects were randomized (2:1:1:1:1:1:1) to receive control vaccine
or one of 6 different formulations of tetravalent vaccine containing
different amounts of HPV L1 VLPs at months (M) 0,1,6. Subjects
were initially followed for 6 months after the last vaccine dose
(Month 12) in a blinded fashion, after which they were invited to
participate in an open-label follow-up study to Month 48.
Study NG-001 (NCT00478621) was  a phase I/II, partially blind,
randomized, controlled trial evaluating an HPV-16/18/33/58 vac-
cine, conducted at 3 centers in Belgium between May  2007 and
October 2008. Subjects were randomized (1:1:1:1:1:1) to receive
control vaccine at M0,1,6 or one of 5 different formulations/dose
schedules of tetravalent vaccine: (i) one formulation with the same
concentration of HPV L1 VLPs (20 g each) and adjuvant system
(AS04) as the control vaccine; (ii) two  formulations with new adju-
vant systems (AS01 and AS02) and containing half the amount of
HPV-33 and -58 L1 VLPs (10 g each) while maintaining the same
amount of HPV-16 and -18 L1 VLPs (20 g each); (iii) ﬁnally the
AS01 formulation was also tested using two different 2-dose sched-
ules: classic 2-dose (M0,6) or accelerated 2-dose (M0,3). Subjects
were followed for 6 months after the last vaccine dose. The trial
was open with regard to dose schedule (2-dose or 3-dose) and was
observer-blind within the 3-dose groups. Syringes were prepared
and administered by qualiﬁed medical personnel not otherwise
involved in the conduct of the study or in the assessment of symp-
toms.
For both trials the randomization list was  generated at Glax-
oSmithKline Biologicals SA using a standard Statistical Analysis
System program; a randomization blocking scheme was  used to
ensure that balance was maintained. Vaccine allocation at all sites
was performed using a central randomization call-in system on
Internet.
Trials were approved by the appropriate Independent Ethics
Committee for each center and carried out in accordance with The
Code of Ethics of the World Medical Association (Declaration of
Helsinki). Written informed consent was  obtained from subjects
prior to the performance of any study-speciﬁc procedures, after
the nature and consequences of the trial had been fully explained.
2.2. Participants
Healthy women  aged 18–25 years at the time of ﬁrst vaccination
who had had no more than 6 lifetime sexual partners were eligible
for each trial. Subjects of childbearing potential had to have used
adequate contraception for 30 days prior to vaccination, have a neg-
ative pregnancy test, and continue contraceptive precautions for 2
months after completion of the vaccination series. Other standard
eligibility criteria are detailed in the ClinicalTrials.gov registry.
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Table 1
Vaccine antigen content, adjuvant and dosing schedule.
Group Group description Adjuvant
system
Dose schedule Dose interval Amount of each HPV L1 VLP (g)
16 18 31 45 33 58
Study TETRA-051 (NCT00231413)
Control Cervarix® AS04 3-dose M0,1,6 20 20 – – – –
A  HPV-16/18/31/45 (20/20/10/10 g) AS04 M0,1,6 AS04 3-dose M0,1,6 20 20 10 10 – –
B  HPV-16/18/31/45 (20/20/20/20 g) AS04 M0,1,6 AS04 3-dose M0,1,6 20 20 20 20 – –
C  HPV-16/18/31/45 (20/30/10/10 g) AS04 M0,1,6 AS04 3-dose M0,1,6 20 30 10 10 – –
D  HPV-16/18/31/45 (20/30/20/20 g) AS04 M0,1,6 AS04 3-dose M0,1,6 20 30 20 20 – –
E  HPV-16/18/31/45 (30/20/10/10 g) AS04 M0,1,6 AS04 3-dose M0,1,6 30 20 10 10 – –
F  HPV-16/18/31/45 (30/20/20/20 g) AS04 M0,1,6 AS04 3-dose M0,1,6 30 20 20 20 – –
Study  NG-001 (NCT00478621)
Control Cervarix® AS04 3-dose M0,1,6 20 20 – – – –
G  HPV-16/18/33/58 (20/20/20/20 g) AS04 M0,1,6 AS04 3-dose M0,1,6 20 20 – – 20 20
H  HPV-16/18/33/58 (20/20/10/10 g) AS01 M0,1,6 AS01 3-dose M0,1,6 20 20 – – 10 10
I  HPV-16/18/33/58 (20/20/10/10 g) AS02 M0,1,6 AS02 3-dose M0,1,6 20 20 – – 10 10
J  HPV-16/18/33/58 (20/20/10/10 g) AS01 M0,3 AS01 2-dose M0,3 20 20 – – 10 10
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.3. Vaccines
All vaccines were developed and manufactured by Glaxo-
mithKline Biologicals SA. The AS04 adjuvant system contains
-O-desacyl-4’-monophosphoryl lipid A (MPL; 50 g) adsorbed on
luminum salt (500 g Al3+). AS04-adjuvanted vaccines were pro-
ided as a liquid suspension in individual pre-ﬁlled syringes for
ingle use (0.5 mL). AS01E is an adjuvant system containing 25 g
PL, 25 g Quillaja saponaria Molina fraction 21 (QS21) and lipo-
ome. AS02W is an adjuvant system containing 25 g MPL  and
5 g QS21 in an oil-in-water emulsion. For AS01 and AS02 vac-
ines, the HPV L1 VLPs were provided as a lyophilized pellet
hich was reconstituted with 0.5 mL  adjuvant immediately prior
o administration.
All vaccines were administered (0.5 mL)  into the deltoid muscle
f the non-dominant arm according to the dosing schedule shown
n Table 1.
.4. Immunogenicity evaluation
The primary objective of each trial was to evaluate antibody
esponses to HPV-16 and -18 one month after the last vaccine
ose. A secondary objective was to evaluate antibody responses to
ther vaccine HPV types (HPV-31/45 or HPV-33/58). Exploratory
bjectives were to evaluate cross-reactive antibodies to other non-
accine HPV types and cell-mediated immunity to vaccine HPV
ypes.
Blood samples for assessment of antibody responses were
rawn at Month 0, one month after each vaccine dose, and 6 months
fter the last vaccine dose. In Study TETRA-051 blood samples
ere also drawn during the open-label follow-up at Months 18, 24,
6 and 48. In both studies, additional blood samples were drawn
rom a subset of subjects at pre-selected study sites for assessment
f cell-mediated immunity. Assays were done at GlaxoSmithKline
iologicals’ laboratories, Rixensart, Belgium.
Quantitation of anti-HPV-16, -18, -31 and -45 antibodies by
nzyme-linked immunosorbent assay (ELISA) and pseudovirion-
ased neutralization assay (PBNA) was based on previously
escribed methodology [14,15]. Multiplex Luminex immunoassay
MLIA) for the simultaneous measurement of anti-HPV-16, -18, -
1, -33, -45, -52 and -58 antibodies is described in Supplementary
ethods.
Memory B-cell frequencies were measured by B-cell ELISPOT
16]. HPV-speciﬁc CD4+ T-cells were identiﬁed as those expressing
wo or more immune markers among CD40 ligand (CD40L),2-dose M0,6 20 20 – – 10 10
interleukin 2 (IL2), tumor necrosis factor alpha (TNF) and inter-
feron gamma  (IFN) after short term in vitro stimulation with
HPV type-speciﬁc L1 VLPs; frequencies were measured by ﬂow
cytometry [17].
2.5. Baseline HPV DNA status
Cervical samples were collected prior to ﬁrst vaccination to
assess baseline HPV DNA status by polymerase chain reaction
(PCR), using SPF10 primers and a reverse hybridization line probe
assay (LiPA25 version1 manufactured by Labo Biomedical Product,
Rijswijk, the Netherlands based on licensed Innogenetics technol-
ogy) [18].
2.6. Reactogenicity and safety
Solicited local symptoms (pain, redness, or swelling at injection
site) and general symptoms (fever, headache, fatigue, gastroin-
testinal symptoms, arthralgia, myalgia, rash or urticaria) occurring
within 7 days after each vaccination were recorded by the subject
using a diary card. Investigators documented the presence/absence
of urticaria/rash within 30 min  after each vaccine dose. Unsolicited
adverse events (AEs) occurring within one month of each vacci-
nation, serious adverse events (SAEs), other medically signiﬁcant
conditions (AEs prompting emergency room or physician visits that
were not related to common diseases), new onset chronic diseases
including new onset autoimmune diseases [16], and pregnancies
were documented by the investigator.
2.7. Statistical methods
In each study, the total vaccinated cohort included all vaccinated
subjects for whom data were available. The according-to-protocol
(ATP) immunogenicity cohort included all evaluable subjects (i.e.,
those meeting all eligibility criteria, complying with the procedures
deﬁned in the protocol, with no elimination criteria during the
study) for whom immunogenicity data were available. The primary
ATP immunogenicity cohort was deﬁned at the end of the active
phase of each study (one month after the last vaccine dose). Sec-
ondary ATP immunogenicity cohorts were deﬁned for subsequent
time points.Seropositivity rates with 95% conﬁdence intervals (CIs) and
geometric mean antibody titers (GMTs) with 95% CIs were cal-
culated. Summaries were stratiﬁed by baseline serostatus. GMTs
were calculated by taking the anti-log of the mean of the log titer
P. Van Damme et al. / Vaccine
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transformations. Antibody titers below the cut-off of the assay were
given an arbitrary value of half the cut-off for the purpose of GMT
calculation.
In TETRA-051, the planned sample size was 376 subjects to give
280 subjects evaluable for immunogenicity (35 subjects for each
tetravalent vaccine and 70 subjects for control). This gave at least
80% power to detect a 2.5-fold difference in HPV-16 or HPV-18
GMTs by ELISA one month after the last vaccine dose (primary
endpoint). Inferential comparisons of GMTs were made using all
subjects in the ATP immunogenicity cohort. The 6 tetravalent vac-
cine groups were compared using a two-way analysis of variance
(ANOVA) F-test model including Factor A (20/20 g, 30/20 g or
20/30 g dose of HPV-16/18), Factor B (10/10 g or 20/20 g dose
of HPV-31/45) and the interaction between A and B. If a statistical
difference was  found (p < 0.025), pair-wise comparisons were to
be made between the 6 groups using Tukey’s multiple comparison
adjustment. The GMTs of the groups in the factorial design which
were not signiﬁcantly different from the group with the highest
HPV-16/18 GMTs were ranked according to dose and compared
in sequential order (groups A, E, C, B, F, D) with the control until
GMTs in the control group were not signiﬁcantly higher than the
test group. HPV-31/45 GMTs were analyzed in a similar way.
In NG-001, the planned sample size was  540 subjects to give
456 subjects evaluable for immunogenicity (76 subjects per group).
This gave 94% power to detect a 2.5-fold difference in HPV-16 or
HPV-18 GMTs by ELISA (primary endpoint) between any of the
6 vaccine groups one month after the last vaccine dose. Inferen-
tial comparisons of GMTs were done on a subcohort of subjects
in the ATP immunogenicity cohort who were initially seronega-
tive and HPV DNA negative at baseline for the corresponding HPV
type. The 6 different vaccine groups were compared using a one-
way ANOVA F-test. If a statistical difference was found (p < 0.025),
pair-wise comparisons were made using Tukey’s multiple compar-
ison adjustment. Similar analyses were done for GMTs measured
by MLIA.
The percentage of subjects with solicited or unsolicited symp-
toms after each vaccine dose and overall was calculated with exact
95% CI.
3. Results
3.1. Trial population
In TETRA-051, 383 women  were vaccinated, 348 (91%) com-
pleted the active phase of the study to one month after the
last vaccine dose, and 297 (78%) were included in the primary
ATP immunogenicity cohort. In NG-001, 540 women were vacci-
nated, 536 (99%) completed the active phase of the study to one
month after the last vaccine dose, and 514 (95%) were included in
the primary ATP immunogenicity cohort. Reasons for withdrawal
from each study and for exclusion from the ATP immunogenic-
ity cohorts are shown in Fig. 1. In both studies, the mean age of
participants was  21 years and the majority (≥93%) were of White
Caucasian/European ethnic heritage (Table 2).
3.2. Antibody responses for HPV-16 and -18
In both studies, all women were seropositive for anti-HPV-
16 and -18 antibodies one month after the last vaccine dose, as
measured by ELISA, and remained seropositive through the last
assessment (Month 48 for TETRA-051 and Month 12 for NG-001).
However, there was  a consistent trend for lower anti-HPV-16 and
-18 GMTs one month after the last vaccine dose when HPV-31/45
or HPV-33/58 L1 VLPs were added to the HPV-16/18 AS04 vaccine
(Fig. 2A and B, respectively). For all vaccines, antibody titers were
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Vaccinated n=383 Vaccinated n=540
Completed to one 
month after last 
vaccine dose n=348
Completed to one 
month after last 
vaccine dose n=536
Withdrawn n=35
• Non-serious adverse event n=2
• Consent withdrawn n=15
• Moved from area n=2
• Lost to follow-up n=15
• Other n=1
Withdrawn n=4
• Consent withdrawn n=1
• Moved from area n=1
• Lost to follow-up n=1
• Other n=1
Assessed 6 months 
after last vaccine 
dose (telephone 
contact only) n=344
Attended visit 6 
months after last 
vaccine dose n=538
Attended Month 18 
visit n=193
Attended Month 24 
visit n=216
Attended Month 36 
visit n=182
Attended Month 48 
visit n=166
Evaluation of HPV- 16/18/31/45 vaccine
(Study TETRA- 051; NCT00231413)
Evaluation of HPV- 16/18/33/58 vaccine
(Study NG- 001; NCT00478621)
ATP 
immunogenicity 
cohort (one month 
after last vaccine 
dose)* n=297
Excluded from ATP immunogenicity 
cohort n=86
• Administration of vaccine
prohibited by protocol n=9 
• Randomization code broken n=1
• Study vaccine not administered
according to protocol n=9
• Inclusion/exclusion  criteria
violation n=2
• Administration of medication
prohibited by the protocol n=3
• Non- compliance  with vaccination
schedule n=18
• Non- compliance  with blood
sampling schedule n=14
• Essential serological data missing
n=30  
ATP 
immunogenicity 
cohort (one month 
after last vaccine 
dose) n=514
Excluded from ATP immunogenicity 
cohort n=26
• Administration of vaccine
prohibited by protocol n=10 
• Randomization failure n=1
• Study vaccine not administered
according to protocol n=2
• Underlying medical condition
prohibited by the protocol n=2
• Non- compliance  with vaccination
schedule n=4
• Non- compliance  with blood
sampling schedule n=6
• Essential serological data missing
n=1  
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Fig. 1. Flow of participants through each study. ATP, according-to-protocol. * For Study TETRA-051, the main cohort for immunogenicity analyses included all subjects in
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ell above those associated with natural infection (i.e., 29.8 ELISA
nits [EU]/mL for anti-HPV-16 and 22.6 EU/mL for anti-HPV-18)
19].
In TETRA-051, there was no statistically signiﬁcant difference
etween the 6 treatment groups in the semi-factorial design in
erms of anti-HPV-16 GMTs (p = 0.3377) or -18 GMTs (p = 0.8364). In
airwise comparisons, GMTs were signiﬁcantly lower for group A
eceiving HPV-16/18/31/45 AS04 (20/20/10/10 g) compared with
ontrol for anti-HPV-16 antibodies (5505 [95% CI: 4386, 6910]
ersus 8742 [7075, 10,801] EU/mL; p = 0.0148) and anti-HPV-18
ntibodies (2963 [2287, 3840] versus 5134 [4229, 6234] EU/mL;
 = 0.0010) (Supplementary Table 1). For anti-HPV-16 GMTs, when
he amount of HPV-16 L1 VLP was increased from 20 g to 30 g
group E: 30/20/10/10 g), there was no statistically signiﬁcant
ifference versus control (7555 [5818, 9811] EU/mL; p = 0.4032),
herefore, no further comparisons were made. For anti-HPV-18
MTs, when the amount of HPV-18 L1 VLP was increased from
0 g to 30 g (group C: 20/30/10/10 g), the difference versus
ontrol was still statistically signiﬁcant (3406 [2757, 4208] EU/mL;
 = 0.0086). When the amount of HPV-31/45 VLPs was increased Study NG-001, the main cohort for immunogenicity analyses included subjects in
PV DNA negative (by PCR) for the corresponding HPV type and the corresponding
from 10 g to 20 g (group B: 20/20/20/20 g), anti-HPV-18 GMTs
were still lower versus control but not statistically different (3643
[2640, 5027] EU/mL; p = 0.0540).
In Study NG-001, in women who  were initially seronega-
tive and HPV DNA negative for the corresponding HPV type,
signiﬁcantly lower anti-HPV-16 GMTs were observed for the
HPV-16/18/33/58 AS04 vaccine containing 20 g of each L1 VLP
compared with control (6775 [5502, 8342] versus 11,246 [9133,
13,847] EU/mL; p = 0.0017) (Supplementary Table 1). However,
anti-HPV-16 GMTs were signiﬁcantly higher for the 3-dose tetrava-
lent vaccine adjuvanted with AS01 (27,645 [22,713, 33,649] EU/mL;
p < 0.0001) or AS02 (17,664 [14,534, 21,468] EU/mL; p = 0.0055)
compared with control. Lower anti-HPV-18 GMTs were observed
for the HPV-16/18/33/58 AS04 vaccine containing 20 g of each
L1 VLP compared with control, although this difference was not
statistically signiﬁcant (2987 [2428, 3675] versus 4332 [3521,
5330] EU/mL; p = 0.0513) (Supplementary Table 1). Anti-HPV-18
GMTs were still lower than control even when different adjuvant
systems were used, though the 3-dose AS01 vaccine elicited the
best anti-HPV-18 response out of the various tetravalent vaccine
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Fig. 2. Antibody titers against vaccine types one month after last vaccine dose by ELISA (ATP immunogenicity cohort). Bars show geometric mean antibody titer (GMT) and
corresponding 95% conﬁdence interval (CI) for each vaccine, determined by enzyme-linked immunosorbent assay (ELISA), one month after the last vaccine dose (Month 7
for  M0,1,6 or M0,6 schedules and Month 4 for M0,3 schedule). Amounts of HPV L1 virus-like particles (VLPs) are in g. Ctrl, control (HPV-16/18 AS04-adjuvanted vaccine).
Data  are shown for the main cohort for inferential analysis for each study, i.e., all subjects in the ATP immunogenicity cohort irrespective of initial serostatus or HPV DNA
status  for Study TETRA-051 (panel A), and subjects in the ATP immunogenicity cohort who  were initially seronegative for HPV antibodies and HPV DNA negative (by PCR)
for  the corresponding HPV type for Study NG-001 (panel B). Note that anti-HPV-33 and anti-HPV-58 titers were not determined by ELISA in Study NG-001.
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ormulations tested. Anti-HPV-16 and -18 GMTs were signiﬁcantly
ower one month after the last vaccine dose when 2 doses (M0,3 or
0,6) of the AS01 formulation were administered, compared with
 doses of the same AS01 formulation.
The results obtained for neutralizing antibodies measured by
BNA in a subset of subjects (Supplementary Fig. 1) were generally
n line with those from ELISA testing, although numbers of subjects
valuated were small.
.3. Antibody responses for non-HPV-16/18 vaccine types
In TETRA-051 (Fig. 2A), there was a signiﬁcant impact of the
PV-31/45 dose on anti-HPV-31 and -45 GMTs. For groups with a
0 g dose of HPV-31 and -45 L1 VLPs (groups B, D and F combined),
he estimated anti-HPV-31 GMT  one month after the last vaccine
ose was approximately 1.4-fold higher than for groups with a
0 g dose (groups A, C and E combined) (12,667 [10,907, 14,711]
ersus 9173 [7867, 10,696] EU/mL; p = 0.0033) and the estimated
nti-HPV-45 GMT  was approximately 1.3-fold higher (7214 [6237,
345] versus 5638 [4855, 6548] EU/mL; p = 0.0209). All tetravalent
accine formulations elicited anti-HPV-31 and anti-HPV-45 GMTs
hat were at least 44-fold higher and 38-fold higher, respectively,
han those associated with natural infection (i.e., 183.5 EU/mL for
nti-HPV-31 and 139.0 EU/mL for anti-HPV-45) [20].
In NG-001 (Supplementary Table 1), in women who were ini-
ially seronegative and HPV DNA negative for the corresponding
PV type, anti-HPV-33 GMTs were signiﬁcantly higher one month
fter the last vaccine dose for the 3-dose AS01 vaccine (21,505
17,842, 25,920] LU/mL) compared with AS02 (12,963 [10,846,
5,493] LU/mL, p = 0.0001) or AS04 (7102 [5869, 8595] LU/mL,
 < 0.0001), with half the HPV-33/58 VLP content of the AS04
etravalent formulation. Anti-HPV-58 GMTs were also signiﬁ-
antly higher for the 3-dose tetravalent vaccine adjuvanted with
S01 (10,897 [9090, 13,064] LU/mL) compared with AS02 (6925
5805, 8261] LU/mL, p = 0.0006) or AS04 (5524 [4556, 6698] LU/mL,
 < 0.0001), with half the HPV-33/58 VLP content of the AS04
etravalent formulation. For the AS01 formulation, anti-HPV-33 and
58 GMTs were signiﬁcantly lower one month after the last vaccine
ose when 2 doses (M0,3 or M0,6) were administered, compared
ith 3 doses.
.4. Cross-reactive antibodies
In Study NG-001, all tetravalent vaccine formulations pro-
uced cross-reacting anti-HPV-31, anti-HPV-45 and anti-HPV-52
MTs which were at least 4-fold, 7-fold and 3-fold higher, respec-
ively, than those associated with natural infection (i.e., 61.6 LU/mL
or anti-HPV-31, 28.7 LU/mL for anti-HPV-45 and 54.5 LU/mL for
nti-HPV-52). The 3-dose tetravalent HPV-16/18/33/58 vaccine
djuvanted with AS01 induced higher levels of cross-reacting anti-
odies to non-vaccine antigens (HPV-31, -45 and -52) one month
fter the last vaccine dose than vaccines adjuvanted with AS02 or
S04 (Supplementary Fig. 2). Cross-reacting antibody responses
ended to be lower when the HPV-16/18/33/58 AS01 vaccine was
dministered on a 2-dose schedule than a 3-dose schedule.
.5. Memory B-cell responses
In TETRA-051 (Fig. 3A), all vaccines induced similar frequen-
ies of HPV-16 and -18 speciﬁc memory B-cells one month after
he last vaccine dose, but the frequencies of HPV-31 and -45 spe-
iﬁc memory B-cells were higher in tetravalent HPV-16/18/31/45
accine groups than in the control group, regardless of VLP con-
entration (median HPV-31 speciﬁc B-cell counts per 106 B-cells
interquartile range] ranged from 2203 [1042–7567] to 5374
2510–7642] for tetravalent formulations versus 263 [194–922] for 32 (2014) 3694–3705
control, and median HPV-45 speciﬁc B-cell counts ranged from 683
[437–2935] to 2246 [760–7538] for tetravalent formulations versus
198 [100–567] for control).
In Study NG-001 (Fig. 3B), the median frequency of HPV-16 spe-
ciﬁc memory B-cells one month after the last vaccine dose was
approximately 2-fold lower for the tetravalent AS04 vaccine (729
[563–1484]) than control (1518 [865–2588]), whereas tetrava-
lent vaccines adjuvanted with AS01 (4550 [2117–7031]) and AS02
(2950 [1384–5014]) induced higher median frequencies of HPV-16
speciﬁc B-cells than control. The median frequency of HPV-18 spe-
ciﬁc B-cells was  approximately 1.6-fold lower for the tetravalent
AS04 vaccine (512 [113–1312]) and 1.5-fold lower for the AS02 vac-
cine (533 [211–1139]) than control (818 [416–2134]), whereas the
AS01 vaccine (919 [430–1493]) induced similar median frequen-
cies of HPV-18 speciﬁc memory B-cells to control. The tetravalent
formulations induced higher frequencies of HPV-33 and -58 spe-
ciﬁc B-cells, compared to cross-reacting HPV-33 and -58 speciﬁc
B-cell responses induced by the control vaccine (HPV-33 speciﬁc
B-cell counts ranged from 1453 [631–3044] to 5678 [2610–8551]
for tetravalent formulations versus 124 [39–317] for control, and
HPV-58 speciﬁc B-cell counts ranged from 1907 [910–2452] to 4006
[2117–5805] for tetravalent formulations versus 112 [34–385]
for control). Comparing the tetravalent formulations, the highest
median B-cell response for all four vaccine types was  induced by
the AS01 formulation, regardless of dose schedule; the AS02 formu-
lation induced an intermediate response and the AS04 formulation
induced a lower response.
3.6. CD4+ T-cell responses
In TETRA-051 (Fig. 4A), the control vaccine induced strong CD4+
T-cell responses to both HPV-16 and -18 one month following last
vaccination, and induced cross-reacting CD4+ T-cell responses to
HPV-31 and -45. All tetravalent formulations also induced high lev-
els of CD4+ T-cells to HPV-16, -18, -31 and -45, regardless of VLP
content.
In Study NG-001 (Fig. 4B), one month after the last vaccine dose,
median frequencies of HPV-16 speciﬁc CD4+ T-cells were similar
for control and tetravalent vaccines. Median frequencies of HPV-
18 speciﬁc CD4+ T-cells were more than 2-fold lower for each of
the tetravalent formulations compared with the control vaccine,
although interquartile ranges overlapped. Frequencies of HPV-33
and -58 speciﬁc CD4+ T-cells induced by the tetravalent vaccine
formulations were similar to the frequencies of cross-reactive CD4+
T-cells induced by the control vaccine, regardless of adjuvant sys-
tem, number of doses or VLP content.
3.7. Reactogenicity and safety
In TETRA-051, reactogenicity proﬁles of the different formula-
tions of the HPV-16/18/31/45 AS04 vaccine were similar across all
six groups and were generally comparable to the proﬁle for the con-
trol vaccine (Supplementary Figs. 3 and 4). There was, however, a
consistent trend for more grade 3 pain in the tetravalent groups
(reported following 8.4–14.9% of doses) compared to the control
group (reported following 6.1% of doses). Through Month 48, 23
subjects reported non-fatal SAEs (Supplementary Table 2). One SAE,
myelitis for a subject in the HPV-16/18/31/45 (20/30/10/10 g)
group, was considered to be possibly related to vaccination by the
investigator. There were two  withdrawals due to non-serious AEs
(pruritus and injection site pain).
In NG-001, there was  a trend for increased reactogenicity
during the 7-day post-vaccination period for tetravalent formula-
tions compared with control vaccine, particularly for formulations
containing AS01 (Supplementary Figs. 3 and 5). Local solicited
symptoms were reported following 91.9% of doses for the control
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Fig. 3. Median number (interquartile range) of HPV-speciﬁc B-cells per 106 B-cells one month after last vaccine dose (ATP immunogenicity cohort). Closed circles show
the  median number of HPV-speciﬁc B-cells per 106 B-cells. Error bars represent the interquartile range. Data are shown for the main analysis cohort for each study, i.e.,
all  subjects in the ATP immunogenicity cohort irrespective of initial serostatus or HPV DNA status for Study TETRA-051 (panel A), and subjects in the ATP immunogenicity
cohort who were initially seronegative for HPV antibodies, HPV DNA negative (by PCR), and B-cell negative for the corresponding HPV type for Study NG-001 (panel B). Ctrl,
control  (HPV-16/18 AS04-adjuvanted vaccine); No., number.
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Fig. 4. Median number (interquartile range) of HPV-speciﬁc CD4+ T-cells per 106 CD4+ T-cells one month after last vaccine dose (ATP immunogenicity cohort). Closed circles
show  median number of HPV-speciﬁc CD4+ T-cells secreting at least 2 different cytokines per 106 CD4+ T-cells. Error bars represent the interquartile range. Data are shown
for  the main analysis cohort for each study, i.e., all subjects in the ATP immunogenicity cohort irrespective of initial serostatus or HPV DNA status for Study TETRA-051 (panel
A),  and subjects in the ATP immunogenicity cohort who  were initially seronegative for HPV antibodies and HPV DNA negative (by PCR) at baseline for the corresponding HPV
type  for Study NG-001 (panel B). Ctrl, control (HPV-16/18 AS04-adjuvanted vaccine); No., number.
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roup and 95.8–98.3% of doses for AS01 groups. General solicited
ymptoms were reported following 55.6% of doses for the control
roup and 68.3–76.1% of doses for AS01 groups. All solicited gen-
ral symptoms, except rash and urticaria, occurred with higher
requency for the AS01 vaccine than for AS04 or AS02 vaccines
Supplementary Fig. 5). Through Month 12, 12 subjects reported
on-fatal SAEs (Supplementary Table 2). None of the SAEs was con-
idered to be possibly related to vaccination by the investigator.
here were no withdrawals due to an AE.
There was no recognizable pattern in terms of timing or types of
AEs, other medically signiﬁcant conditions, or new onset chronic
iseases (including new onset autoimmune diseases) reported
cross the vaccine groups in either study.
. Discussion
It is well documented that inclusion of additional antigens
n non-HPV vaccines can have a positive or negative effect on
mmunogenicity and reactogenicity [21–26]. In two trials evaluat-
ng investigational adjuvanted tetravalent HPV vaccines, we found
hat new HPV L1 VLPs (HPV-31/45 or HPV-33/58) introduced into
he vaccine were immunogenic, but tended to lower the magnitude
f anti-HPV-16 and -18 antibody responses, compared with the
icensed HPV-16/18 AS04-adjuvanted vaccine. Whether this would
esult in a reduction in either the quality or duration of protec-
ion against HPV infection or other clinical endpoints is not known,
ince immunological correlates of protection for HPV have not been
eﬁned. Thus, care needs to be used interpreting these results.
For anti-HPV-16 antibodies, the immune interference could be
vercome by a change in vaccine formulation (either by increas-
ng the dose of HPV-16 L1 VLPs, or by using a different adjuvant
ystem). In fact, a particularly high anti-HPV-16 antibody response
as elicited when the tetravalent HPV-16/18/33/58 vaccine was
djuvanted with AS01 or AS02, compared with the control vaccine.
his ﬁnding was supported by the detection of higher HPV-16 spe-
iﬁc memory B-cell responses for formulations containing AS01 and
S02, although these adjuvant systems did not notably impact on
PV-16 speciﬁc CD4+ T-cell responses. An evaluation of the inter-
ction of speciﬁc CD4+ T-cell help for memory B-cell maturation
nd antibody afﬁnity may  shed some light on the results observed.
The nature of the negative immune interference with regard to
nti-HPV-18 humoral and cellular immunity was more complex
nd could not always be overcome by increasing the dose of HPV-
8 L1 VLPs, or by using a different adjuvant system. Interestingly,
e observed that increasing the amount of HPV-31/45 VLPs from
0 g to 20 g did improve the anti-HPV-18 immunogenicity of a
etravalent HPV-16/18/31/45 vaccine, although anti-HPV-18 GMTs
ere still lower than those elicited by the control vaccine. This was
resumably because of enhanced induction of cross-reactive HPV-
8 antibodies induced by HPV-45 (both are A7 species of HPV).
As expected, we found that speciﬁc antibody responses to the
dditional HPV L1 VLPs introduced in the tetravalent vaccines
HPV-31 and -45 or HPV-33 and -58) were signiﬁcantly higher
ompared with cross-reacting antibodies induced by the control
accine. However, it is not possible to predict from the two studies
eported herein whether enhanced immune responses with poly-
alent vaccines against a broader range of oncogenic HPV types will
ranslate into higher clinical efﬁcacy than previously reported [11].
Although the precise contribution of HPV-16, -33 and -58 to
ross-reactivity against other species of HPV (HPV-31 and HPV-
2) cannot be deﬁned, it is clear that adjuvantation with AS01 has major impact on the cross-reactive behavior of the tetravalent
PV-16/18/33/58 vaccine. A tentative explanation for this relates
o the ability of AS01 to stimulate the innate immune response, to
nhance or modulate antigen-speciﬁc antibody and T cell-mediated 32 (2014) 3694–3705 3703
responses [13]. Major type-speciﬁc regions on HPV L1 VLPs that are
surface exposed and conformation dependent have been identiﬁed
for a few HPV types, but very little is known about the regions of
HPV L1 VLPs important for cross-reactivity [27].
Although the correlates of immunity for HPV remain unknown,
it has been demonstrated in seropositive women who  cleared an
HPV-16 or -18 infection that higher type-speciﬁc HPV antibody
titers are associated with a reduced risk of re-infection with the
same HPV type [28]. It is unknown if antibodies are a surrogate
marker for immunity and if this same association will be seen in
vaccinated women  whose antibody responses are typically much
higher than those seen after natural infection. However, it has pre-
viously been shown that the HPV-16/18 AS04-adjuvanted vaccine
induces cross-neutralizing antibodies that may  mediate cross-
protection [29]. Further, it has been suggested that the magnitude
of the immune response may  represent a determinant of duration
of protection, although this remains to be proven [16,17,20].
When the HPV-16/18/33/58 AS01 vaccine was administered as
a 2-dose regimen, the HPV type-speciﬁc antibody response to all
HPV antigens tested was  lower than when receiving 3 doses of the
same formulation. However, the NG-001 study was not designed to
formally evaluate non-inferiority of immune responses for differ-
ent dose schedules, and was  performed in an older age group than
previous 2-dose studies. It has previously been shown that anti-
HPV-16 and -18 antibody levels elicited by 2-dose schedules of the
licensed HPV-16/18 AS04-adjuvanted vaccine may  be adequate for
girls aged 9–14 years [30], however, further investigation is ongo-
ing. Furthermore, in a large Costa Rican trial in women  aged 18–25
years it was  shown that 2 doses of the HPV-16/18 vaccine were
as protective against persistent infection as 3 doses over a 4-year
period post-vaccination [31].
Although all tetravalent formulations had an acceptable reacto-
genicity and safety proﬁle, there was  a tendency toward an increase
in reactogenicity when additional HPV L1 VLPs were added to the
vaccine, especially with formulations containing AS01.
It was not the aim of this paper to directly compare the two
studies reported herein. The rationale was to present the results
of two  separate studies (with different design, number of par-
ticipants, investigational products, study cohorts, and data sets
analyzed) that led to very similar results and support the same
observation, i.e., that adding different HPV antigens to the licensed
HPV-16/18 AS04-adjuvanted vaccine can cause negative immune
interference with regard to HPV-16/18 humoral and/or cellular
immunity, although the clinical relevance of this immune interfer-
ence is unknown. Even though the sub-cohorts of subjects under
analysis were not the same, the authors believe that results of
both studies, when taken together, strengthen the conclusion on
immune interference.
Immune interference is complex and cannot necessarily be over-
come by increasing the dose of the affected HPV L1 VLP, or by
changing the adjuvant, but may  be overcome by altering the relative
ratios of the HPV L1 VLP components of the vaccine. When develop-
ing a vaccine, consideration should be given to selecting the optimal
combination of antigens and adjuvants, taking into account the
intended purpose and target population of the vaccine. Although
the AS04 adjuvant system is adequate for the bivalent HPV-16/18
vaccine, next-generation polyvalent vaccines may require the use
of other adjuvant systems or technologies.
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